

PROXY/VOTING BY CORRESPONDENCE FORM

The annual general meeting of Scandion Oncology A/S ("Scandion Oncology" or the "Company")
on 26 April 2023, at 2.00 p.m. (CET)
at the Company's address Fruebjergvej 3, DK-2100 Copenhagen Ø, Denmark

Name of shareholder: _____
Address: _____
Zip code and city: _____

I, the undersigned, hereby grant authority by proxy or vote by correspondence at the annual general meeting of Scandion Oncology to be held on **26 April 2023** as set out below:

Please mark the appropriate box A), B), C), or D). Please note that it is only possible either to grant authority by proxy or to vote by correspondence.

A) Proxy is given to an identified third person:

Name and address of the proxy holder (CAPITAL LETTERS)

B) Proxy is given to the board of directors (with a right of substitution) to vote in accordance with the recommendations of the board of directors as stated in the table below.

C) Proxy is given to the board of directors (with a right of substitution) to vote in accordance with the voting directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your directions.

D) The vote by correspondence is given in accordance with the voting directions given below. Please mark the box "FOR", "AGAINST" or "ABSTAIN" to indicate your directions. The vote by correspondence is irrevocable.

Items on the agenda (the full agenda is included in the notice of the meeting)	FOR	AGAINST	ABSTAIN	The board's recommendation
1. Election of chairman of the meeting	<input type="checkbox"/>	*	<input type="checkbox"/>	FOR
2. Report from the board of directors on the Company's activities in the past year	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
3. Presentation of the audited annual report for approval	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
4. Proposal of notice of discharge for the board of directors and the executive board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
5. Decision on appropriation of profit or loss as recorded in the approved annual report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
6. Proposal of approval of the board of directors' fee for 2023	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	FOR
7. Election of members to the board of directors A) Re-election of Martin Møller B) Re-election of Jørgen Bardenfleth C) Re-election of Alejandra Mørk D) Re-election of Keld Flintholm Jørgensen E) Re-election of Martine Van Vugt	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	*	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	FOR

8. Election of auditor	□	*	□	FOR
------------------------	---	---	---	-----

**In connection with the election of persons (election of chairman of the meeting (item 1), members of the board of directors (item 7) and auditor (item 8), is it legally speaking only possible to vote in favour of the proposed candidates or in favour of alternative candidates proposed for the positions in question. Consequently, the proxy/voting by correspondence form cannot be used to vote against the proposed candidates.*

A form that has only been dated and signed shall be considered as a proxy given to the board of directors to vote in accordance with the recommendations of the board of directors as they appear in the table above.

The proxy shall apply to all subjects discussed at the annual general meeting. If new proposals are presented and put to the vote, including proposals for amendments, the proxy holder shall be entitled to vote on your behalf in accordance with his or her own convictions.

The proxy/vote by correspondence applies to the number of shares in the possession of the undersigned on the date of registration, 19 April 2023. The shareholding is calculated on the basis of the entry in the Company's register of shareholders and notifications on ownership that the Company has received, but not yet entered in the register of shareholders.

The Company requests that the completed and signed form is received by the Company at the address Fruebjergvej 3, DK-2100 Copenhagen Ø, or by e-mail to: gm@scandiononcology.com no later than 24 April 2023 at 11.59 p.m. (CET).

				2	0	2	3
--	--	--	--	---	---	---	---

Signature